Cathleen Varley
Registered Nurse · New York, NYNPI 1134169576
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Merck at 31.2% of the total. Reporting peaked in 2024 at $7,075 and has fallen 83.2% since, to $1,186 in 2025. Among registered nurse clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $55.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Abbott$3K
- Bayer$1K
- Novo Nordisk$694
- Novartis$606
- Boehringer Ingelheim$552
- plus $3K from 18 others
What the payments were for
- Consulting fees$4,24232%
- Travel & lodging$1,0858%
- Food & beverage$7,78158%
- Education$1011%
- Other$1381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $4,163 |
| Abbott | 48 | $3,166 |
| Bayer | 2 | $1,262 |
| Novo Nordisk | 30 | $694 |
| Novartis | 38 | $606 |
| Boehringer Ingelheim | 22 | $552 |
| AstraZeneca | 19 | $479 |
| Boston Scientific | 8 | $435 |
| Scpharmaceuticals Inc. | 9 | $406 |
| E.r. Squibb & Sons, L.L.C. | 9 | $294 |
| Alnylam Pharmaceuticals Inc. | 2 | $228 |
| Pfizer | 7 | $209 |
| Esperion Therapeutics, Inc. | 7 | $190 |
| Amgen | 7 | $161 |
| Baxter Healthcare | 1 | $138 |
| CMP Pharma, Inc. | 3 | $134 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 1 | $39 |
| Akcea Therapeutics, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Abiomed | 1 | $18 |
| Philips North America LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,675
- VERQUVO$1,553
- Kerendia$1,242
- CardioMEMS HF System$442
- FUROSCIX$273
- CAMZYOS$138
- ONPATTRO$135
- Ozempic$125
- WAINUA$109
- LEQVIO$100
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$100
How this compares
$13,346 in reported general payments places this provider in the 95th percentile of 446 registered nurse providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 18 | $675,062 |
| EntrestoSacubitril/Valsartan | 337 | $306,754 |
| JardianceEmpagliflozin | 287 | $229,484 |
| FarxigaDapagliflozin Propanediol | 124 | $96,874 |
| EliquisApixaban | 114 | $87,331 |
| XareltoRivaroxaban | 23 | $13,199 |
| VerquvoVericiguat | 18 | $11,265 |
| Metoprolol Succinate | 417 | $4,394 |
| Torsemide | 403 | $4,347 |
| Atorvastatin Calcium | 213 | $2,026 |
| Valsartan | 52 | $1,776 |
| Spironolactone | 246 | $927 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 83 | $662 |
| Colchicine | 13 | $534 |
| Rosuvastatin Calcium | 15 | $350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $209 | $762,393132 claims |
| NovartisEntresto | $606 | $306,754337 claims |
| Boehringer IngelheimJardiance | $552 | $229,484287 claims |
| AstraZenecaFarxiga | $479 | $96,874124 claims |
| Johnson & JohnsonXarelto | $20 | $13,19923 claims |
| MerckVerquvo | $4,163 | $11,26518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 446 registered nurse providers in New York.
Other registered nurse in New York
- Jane SeleyNew York$20K
- Hilary NierenbergNew York$4K
- Kerry BoyceNew York$3K
- Kelly RusinekNew York$2K
- Esther ChongNew York$1K
- Judy JosephNew York$477
- Chia-Wei LinBronx$15K
- Hyojin KangOakland Gardens$7K
- Barbara RysWarwick$7K
- Janet KelskeWest Bay Shore$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.